MedTrace Logo

Lenalidomide and High-Dose Melphalan

NCT01079936 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2016-06-06

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of Revlimid (lenalidomide) and high-dose Alkeran (melphalan) that can be given to patients with multiple myeloma who will receive an autologous stem cell transplantation. The safety of this combination therapy will also be studied.

Conditions

  • Myeloma
  • Stem Cell Transplantation

Interventions

DRUG

Lenalidomide

Beginning dose level 25 mg by mouth (PO) on Days -8 to -2

DRUG

Melphalan

Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion

PROCEDURE

Stem Cell Infusion

Stem cell infusion on Day 0.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Muzaffar H. Qazilbash, MD · UT MD Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01079936 on ClinicalTrials.gov